Patent: 10,072,098
✉ Email this page to a colleague
Summary for Patent: 10,072,098
| Title: | Pseudomonas aeruginosa PCRV binding single variable domain antibodies |
| Abstract: | Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the \"first\" immunoglobulin single variable domain and the \"second\" immunoglobulin single variable domain have different paratopes. |
| Inventor(s): | De Tavernier; Evelyn (Deurle, BE), Union; Ann (Aalter, BE), Dombrecht; Bruno (Heusden, BE), Hermans; Guy (Merelbeke, BE), Morizzo; Erika (Ghent, BE) |
| Assignee: | Ablynx N.V. (Ghent-Zwijnaarde, BE) |
| Application Number: | 14/382,027 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,072,098
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Grifols Therapeutics Llc | ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 | albumin (human) | For Injection | 101138 | 10/21/1942 | ⤷ Try a Trial | 2032-03-02 |
| Baxalta Us Inc. | BUMINATE, FLEXBUMIN | albumin (human) | Injection | 101452 | 03/03/1954 | ⤷ Try a Trial | 2032-03-02 |
| Csl Behring Ag | ALBURX | albumin (human) | Injection | 102366 | 07/23/1976 | ⤷ Try a Trial | 2032-03-02 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
